In 2014, Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson) introduced Invokamet in an attempt to capitalize on the extremely profitable new generation diabetes drug market.
However, it now appears that inadequate warnings may have been provided about potential health risks with Invokamet, including kidney failure.
Invokamet Kidney Failure
Kidney failure occurs when your kidneys stop functioning without the use of dialysis or a kidney transplant. Kidneys help filter waste products from the blood. They are also involved in regulating blood pressure, electrolyte balance, and red blood cell production.
When your kidneys stop properly functioning, waste products, fluids, and electrolytes build up in the body and can cause weakness, shortness of breath, lethargy, confusion, abnormal heart rhythms and sudden death.
Based on the way the Invokamet works, some experts have suggested that the drug maker knew or should have known about the potential kidney failure risks with Invokamet before the drug was released to the market.
Concerns have also been raised about whether the benefits provided in treating type-2 diabetes through new generation diabetes drugs outweigh the potential risks of side effects like kidney failure.
About Invokamet
While Invokamet is a more recent formulation of this class of diabetes medications, its “parent” drug, Invokana, is reported to exceed two million prescriptions annually. Janssen’s Invokana/Invokamet drugs, along with other SGLT2 inhibitors, are expected to bring between $2 and $5 billion in annual revenue to the pharmaceutical industry.
The class of diabetes drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors work by helping the kidneys remove sugar from the body by excreting it in urine. This is designed to increase glucose production and lower blood glucose levels among diabetics.
Invokamet is two medicines in one pill. It combines canagliflozin (Invokana) with metformin. The addition of metformin decreases the production of glucose in the liver.
Canagliflozin was not the first SGLT2 inhibitor to apply for FDA approval. The first drug was Farxiga, which was originally rejected due to concerns about its effects on the liver.
Canagliflozin, one of the Invokamet ingredients, was the second to apply and the first approved in 2013. Metformin, the other Invokamet ingredient was approved under the brand name “Glucophage” in 2003 and has been used in combination with many other antidiabetics.
Based on adverse event reports submitted involving problems with Invokamet and other SGLT2 inhibitors, it now appears that side effects of the drugs may lead to serious and potentially life threatening complications that were not adequately disclosed to consumers or the medical community in the Invokamet warnings.
If adequate warnings had been provided about the potential risk of Invokamet side effects, individuals may have been able to avoid suffering serious and potentially life threatening kidney failure and other injuries.
If you or a loved one suffered significant side effects from the diabetes medication Invokamet, you may have a legal claim. You could be eligible to take legal action against the drug manufacturer and seek compensation for your medical expenses, lost wages, pain and suffering, and more. Invokamet lawyers are available for a free case evaluation.
In general, diabetes medication lawsuits are filed individually by each plaintiff and are not class actions.
Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual lawsuit or class action lawsuit is best for you. Hurry — statutes of limitations may apply.
Top Class Actions is a Proud Member of the American Bar Association
LEGAL INFORMATION IS NOT LEGAL ADVICE
Top Class Actions Legal Statement
©2008 – 2015 Top Class Actions® LLC
Various Trademarks held by their respective owners
Get Help – It’s Free
Join a Free Diabetes Medication Class Action Lawsuit Investigation
If you or a loved one suffered ketoacidosis or kidney failure after taking Invokana, Invokamet, Farxiga, Xigduo XR, Jardiance or Glyxambi, you may have a legal claim. See if you qualify to pursue compensation and join a free diabetes medication class action lawsuit investigation by submitting your information for a free case evaluation.
An attorney will contact you if you qualify to discuss the details of your potential case.
- First Name*
- Last Name*
- Street Address*
- Apt. #
- City*
- State*
AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareDistrict of ColumbiaFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWest VirginiaWisconsinWyomingArmed Forces AmericasArmed Forces EuropeArmed Forces Pacific
- Zip Code*
- Phone*
- Email*
- Please select the diabetes medication(s) you have taken:*
-
Invokana (canagliflozin)
-
Invokamet (canagliflozin and metformin)
-
Farxiga (dapagliflozin)
-
Xigduo XR (dapagliflozin and metformin extended-release)
-
Jardiance (empaglifloziin)
-
Glyxambi (empagliflozin and linagliptin)
-
- When did you take the diabetes medication(s)?*
- Please select the symptoms you or your loved one were medically diagnosed with:*
-
Ketoacidosis
-
Kidney Failure
-
Myocardial Infarction (Heart Attack)
-
Bone fracture(s)
-
Not Listed (please detail the symptoms in the comments section if this is selected)
-
No diagnosis/injury
-
- ¿Necesita un orador español?
- Yes
- No
- Please enter any additional details you would like the staff reviewing your submission to know.*
- I understand and agree that submitting this form does not create an attorney-client relationship and that the information I submit is not confidential or privileged and may be shared.*
-
Yes
-
-
if(typeof gf_global == ‘undefined’) var gf_global = {“gf_currency_config”:{“name”:”U.S. Dollar”,”symbol_left”:”$”,”symbol_right”:””,”symbol_padding”:””,”thousand_separator”:”,”,”decimal_separator”:”.”,”decimals”:2},”base_url”:”http:\/\/topclassactions.com\/wp-content\/plugins\/gravityforms”,”number_formats”:[],”spinnerUrl”:”http:\/\/topclassactions.com\/wp-content\/plugins\/gravityforms\/images\/spinner.gif”};jQuery(document).bind(‘gform_post_render’, function(event, formId, currentPage){if(formId == 144) {gformInitChosenFields(‘#input_144_5′,’No results matched’);if(!/(android)/i.test(navigator.userAgent)){jQuery(‘#input_144_7’).mask(‘(999) 999-9999’).bind(‘keypress’, function(e){if(e.which == 13){jQuery(this).blur();} } );}} } );jQuery(document).bind(‘gform_post_conditional_logic’, function(event, formId, fields, isInit){gformInitChosenFields(‘#input_144_5′,’No results matched’);} ); jQuery(document).ready(function(){jQuery(document).trigger(‘gform_post_render’, [144, 1]) } );
The post Invokamet Health Risks May Include Kidney Failure appeared first on Top Class Actions.
No comments:
Post a Comment